Linking MLL Leukemia with Integrin Signaling  by Zeisig, Bernd B. & So, Chi Wai Eric
Cancer Cell
PreviewsMartin, M., Ruiz, A., Borrego, M.R., Barnadas, A.,
Gonzalez, S., Calvo, L., Vila, M.M., Anton, A.,
Rodriguez-Lescure, A., Segui-Palmer, M.A., et al.
(2013). J. Clin. Oncol., Epub ahead of print.
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini,
K.S., Viale, G., Loi, S., Bradbury, I., Bliss, J.M.,Azim, H.A., Jr., Ellis, P., et al. (2012). J. Clin. Oncol.
30, 1879–1887.
Siegel, R., Naishadham, D., and Jemal, A. (2013).
CA Cancer J. Clin. 63, 11–30.
Thompson, A.M., Jordan, L.B., Quinlan, P., Ander-
son, E., Skene, A., Dewar, J.A., and Purdie, C.A.;CancerBreast Recurrence in Tissues Study Group.
(2010). Breast Cancer Res 12, R92.
Zhao, Y., Burikhanov, R., Qiu, S., Lele, S.M.,
Jennings, C.D., Bondada, S., Spear, B., and
Rangnekar, V.M. (2007). Cancer Res. 67, 9276–
9285.Linking MLL Leukemia with Integrin SignalingBernd B. Zeisig1 and Chi Wai Eric So1,*
1Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine, King’s College London, London SE5 9NU, UK
*Correspondence: eric.so@kcl.ac.uk
http://dx.doi.org/10.1016/j.ccr.2013.06.011
Identification of tractable signaling molecules essential for leukemogenesis facilitates the development of
effective targeted therapies. In this issue of Cancer Cell, Miller and colleagues report that Integrin Beta 3,
which is largely dispensable for normal hematopoiesis, plays an important role and is a potential therapeutic
target in mixed lineage leukemia.Acutemyeloid leukemia (AML) is a hetero-
geneous clonal disorder of hematopoietic
stem and progenitor cells characterized
by the presence of recurring chimeric
transcription factors and/or mutations
affecting key components of the tran-
scription machinery. With the exception
of acute promyelocytic leukemia, which
is uniquely sensitive to targeted therapies
using all-trans retinoic acid and arsenic
trioxide, treatment for other AML has not
changed in the past decades, and thus
AML remains a highly fatal disease with
very poor overall survival rates (Zeisig
et al., 2012). Among them, recurrent
genetic abnormalities involving chimeric
fusion of the mixed lineage leukemia
(MLL) gene at chromosome 11q23 repre-
sents one of the worst prognostic AML
subgroups and urgently needs the devel-
opment of novel and effective therapeutic
interventions. Given the important role of
MLL fusions in initiating and maintaining
the disease, major effort has been made
in dissecting the molecular functions of
these initiating events. As a result, a
number of critical molecules associated
with MLL fusion transcription complexes,
including various epigenetic modifying
enzymes, have been identified and
demonstrated as potential therapeutic
targets forMLL (Figure 1A). In spite of their
promise in preclinical disease models, thedevelopment of specific inhibitors target-
ing the transcription machinery is still in
a very early phase and a bottleneck for
translating these results into the clinics.
Approaches in identifying more tractable
signaling molecules in which small-mole-
cule inhibitors are readily available there-
fore appear as attractive alternatives.
In this issue of Cancer Cell, Miller et al.
(2013) reported their in vivo shRNA
screening approach to identify novel reg-
ulators required for MLL-AF9 leukemia in
a mouse model with a focused library tar-
geting 268 known or candidate cancer-
associated genes. Using massively
parallel sequencing to determine the rela-
tive distribution of each shRNA at different
time points, 60 candidate genes targeted
by at least two different shRNAs were
found to be significantly depleted in vivo.
Among them were Ctnnb1, Myb, and
Mef2c, which have been previously
shown as critical targets for MLL. In addi-
tion, Itgb3 was also among the most
highly depleted, suggesting that Itgb3
could represent a novel target for MLL-
AF9 leukemia. Its functional significance
was further validated with individual
shRNAs targeting Itgb3, which resulted
in a significant delay of the AML disease
onset in recipient mice. Integrins are
known to mediate many cellular pro-
cesses and interact with the micro-environment. Consistently, the authors
showed that leukemic cells with a
reduced level of Itgb3 had a compro-
mised ability to home and engraft in the
bone marrow upon transplantation in
both mouse and humanized xenograft
models. On the other hand, successfully
engrafted MLL cells carrying Itgb3 shRNA
progressively declined over time, indi-
cating a critical function of Itgb3 in medi-
ating leukemic proliferation in addition to
homing. The pathological importance of
Itgb3 signaling in MLL-AF9 leukemia was
further demonstrated by the depletion of
leukemic clone with shRNAs targeting its
heterodimeric partner, Itgav. Interestingly,
the loss of Itgb3 is largely dispensable for
normal hematopoiesis as Itgb3 germline
knockout mice show no obvious hemato-
poietic defect and human patients with
biallelic ITGB3 mutation do not have a
bone marrow failure phenotype. In terms
of homing, Itgb3 knockdown did not
impair hematopoietic reconstitution of
normal LSK cells over a 24-week period
after transplantation, although confirma-
tion of persistent Itgb3 knockdown in the
transplanted cells was not demonstrated.
Nevertheless, these data together reveal
Itgb3 as a novel therapeutic target for
MLL (Figure 1B).
To gain further mechanistic insight into
Itgb3 signaling in AML, a secondary in vivoCell 24, July 8, 2013 ª2013 Elsevier Inc. 5
Figure 1. Emerging Targeted Therapies in MLL and Its New Link with Itgb3/Syk Signaling
(A) MLL cells reside and interact with the bone marrow niche. MLL fusion transcription complexes (note:
for simplicity, not all components are displayed) regulate and maintain the expression of downstream
target genes such as HOX, resulting in active LSC transcriptional programs, which drive the proliferation
and self-renewal of AML cells. While targeting critical components of the MLL fusion complexes have
shown promise in preclinical models, the development of relevant small-molecule inhibitors is still in its
early phase. On the other hand, additional signaling pathways can contribute to and may play important
roles in the transformation phenotype.
(B) The ITGB3/SYK signaling axis has been suggested as a novel avenue for targeting MLL. Here, ITGB3/
ITGAV heterodimer expressed on MLL cells mediates the interaction with ligands on the surface of stroma
cells in the bonemarrow niche. This interaction triggers a signaling cascade that involves Syk and possibly
other factors (X and Y) critical for the proliferation of AML cells. Inhibition of the ITGB3/SYK axis up-
regulates transcriptional differentiation programs and downregulates LSC programs, leading to the
suppression of MLL cell growth. However, the major functions of ITGB3 in MLL remain to be determined
as its suppression will have both non-cell autonomous and cell autonomous effects. Moreover, the cross-
talk between ITGB3/SYK signaling and MLL fusion-driven transcriptional programs in mediating leukemic
transformation is still largely unknown.
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targeting 19 known components of the
integrin pathway (Miller et al., 2013). In
addition to Vav1, Rac2, RhoA and CD47,
shRNAs targeting Syk were depleted by
more than 10-fold. Syk is highly ex-
pressed in AML cells (Tomasson et al.,
2008) and has been previously reported
as an important target for AML, including
MLL (Hahn et al., 2009). Consistently, a
gene expression signature generated us-
ing R406, an ATP competitive kinase in-
hibitor targeting Syk in leukemia, showed
a strong correlation with the gene expres-
sion signature after knockdown of Itgb3,
although R406 exhibits a wide activity
toward other kinases such as FLT3,
c-KIT, and JNK at almost equipotent
levels (Braselmann et al., 2006; Mo´csai
et al., 2010). Moreover, treatment of
leukemic cells with R406 in an OP9 cocul-
ture assay reduced the cobblestone area
in a dose-dependent manner, further
suggesting a critical function of Syk in
mediating Itgb3 signaling in leukemia
(Figure 1B).6 Cancer Cell 24, July 8, 2013 ª2013 ElsevieThe identification of tractable signaling
molecules such as Itgb3, which is critical
for leukemia development, and the avail-
ability of Syk inhibitors that have already
been shown effective in the treatment of
allergy, autoimmune diseases, and B cell
malignancies (Mo´csai et al., 2010) bring
hope to the rapid translation of these find-
ings to the clinics. This being said, there
remain a number of outstanding issues
requiring further investigations. In con-
trast to targeting MLL fusion transcription
complexes, the functional relationship
between Itgb3/Syk and MLL fusion in
leukemogenesis remains largely unknown
(Figure 1). Will targeting Itgb3 directly
affect the leukemic cells, their interaction
with the microenvironment, or both? It is
well known that AML cells, including
MLL-AF9 transformed cells, interact with
the bone marrow microenvironment,
most likely within the endosteal region
(Ishikawa et al., 2007). This interaction is
thought to be critical for cell survival and
has been shown to influence the lineage
fate of MLL-AF9 leukemia (Wei et al.,r Inc.2008). Consistently, the data provided
by Miller et al. (2013) suggest a critical
function of Itgb3 in both leukemic cell
homing and interaction with the stromal
cells. Its inhibition resulted in extended
disease latency upon transplantation in
the mouse models. This is, however,
different from the situation in human
patients, where AML cells already reside
in the niche. A conditional inactivation of
Itgb3 upon leukemic cell engraftment
may provide unique insights and help pre-
dict the efficacy of inhibiting the Itgb3
pathway in human leukemia. On the other
hand, whether the Itgb3-Syk pathway is
also active and essential in AML stem
cells will require further investigations.
Similarly, the specificity of Syk inhibitor
and its efficacy on eradicating AML stem
cells have not been demonstrated.
Finally, mTOR (Carnevale et al., 2013)
and STAT3/5 (Oellerich et al., 2013) have
recently been identified as downstream
mediators of Syk in AML cells; it will be
of interest to determine if similar or
distinctive pathways are operated in
MLL. Altogether, the identification of the
critical functions of Itgb3-Syk axis in
MLL has opened up an exciting new
research area and potentially provides a
novel tractable therapeutic target for this
aggressive form of leukemia.
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Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER+) breast cancer. In this issue of
Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the
response of xenografts from primary ER+ breast tumors to endocrine therapy and reduces tamoxifen-
induced endometrial hyperplasia, a strategy with potential clinical applicability.In this issue of Cancer Cell, encouraging
data are presented on a new approach
to enhancing the efficacy of endocrine
treatment in estrogen receptor-positive
(ER+) breast cancer by negating the
antiapoptotic properties of BCL-2 by
the use of BH3 mimetics (Vaillant et al.,
2013).
Breast cancer is the most common
invasive malignant disease in women.
Approximately 80% of breast cancer pa-
tients at primary diagnosis present with
tumors that are ER+. Estrogen mediates
its effects by binding to the ER. Estro-
gen-bound ER associates classically
with estrogen response elements on
target genes controlling proliferation and
cell survival (Ali and Coombes, 2002).
Gene expression profiling has revealed a
high degree of molecular heterogeneity
in ER+ breast cancer, which is associated
with variable clinical outcomes (Sørlie
et al., 2001). Based on gene expression
profiles, ER+ breast cancer is classified
into two groups: luminal A and luminal B.
Luminal A tumors are characterized by a
greater expression of estrogen-regulated
genes and markers associated with
luminal breast epithelial cells, whereas
these features are less apparent in luminal
B tumors, which have a greater expres-sion of proliferation-associated genes
and poorer prognosis.
Almost all patients with ER+ breast can-
cer are treated for at least 5 years with
endocrine therapy, which aims to deprive
the cancer of estrogenic signaling either
by competitive antagonistic binding of
antiestrogens (e.g., tamoxifen or fulves-
trant) or by suppressing estrogen synthe-
sis (using GnRH agonists in premeno-
pausal patients and using aromatase
inhibitors in postmenopausal patients)
(Dowsett and Howell, 2002). Such treat-
ment radically reduces the chances of
disease recurrence and death from breast
cancer. However, the beneficial effects of
endocrine treatment are attenuated in
some tumors by their ability to circumvent
the need for steroid hormones, while, in
most cases, retaining the nuclear steroid
receptors (Ali and Coombes, 2002). The
identification of the factors and pathways
responsible for the development of these
resistant conditions remains paramount
for the design of new diagnostics and
therapeutic regimens.
Tumor regressions resulting from
endocrine therapies are generally rela-
tively slow and are driven primarily by a
reduction in cell proliferation but not
increased apoptosis (Dowsett et al.,2005). Apoptosis is a highly regulated
process responsible for the removal of
damaged and unnecessary cells. The
dynamic interplay between pro-death
proteins (BAX, BAK, BAD, BIM, NOXA,
and PUMA) and pro-survival proteins
(BCL-2, BCL-XL, and BCL-W) controls
this programmed cell death (Chipuk
et al., 2010) (Figure 1). Shifting the bal-
ance between these opposing proteins
may allow the therapist to selectively
enhance apoptosis in malignant cells.
The tumorigenic potential of the over-
expression of BCL-2 was first described
as a result of the chromosomal transloca-
tion seen in subsets of non-Hodgkin’s
lymphoma, where it has been found to
be pathognomic and associated with
adverse outcome. Enhanced expression
of BCL-2 has been identified in other
malignancies, including breast cancer,
where its pathological function is less
clear. Notably, in breast cancer, BCL-2
is expressed almost exclusively in ER+
disease, where it is a favorable prognostic
factor. However, there is a ‘‘disconnect’’
in this regard between BCL-2 protein
and transcript, with the prognostic sig-
nificance of BCL-2 transcript levels
being very different from those of protein
levels. Although BCL-2 has prognosticCell 24, July 8, 2013 ª2013 Elsevier Inc. 7
